Multi-omics Market Size & Share, by Product & Service (Products {Instruments, Consumables, Software}, Services); Type (Single-Cell Multiomics, Bulk Multiomics); Platform (Genomics, Transcriptomics, Proteomics, Metabolomics, Integrated Omics Platforms); Application (Cell Biology, Oncology, Neurology, Immunology); End-Use (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 6091
  • Published Date: May 30, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Multi-omics Market size was over USD 2.5 Billion in 2023 and is likely to exceed USD 15.5 Billion by the end of 2036, growing at over 15.1% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of multi-omics is assessed at USD 2.87 Billion.

The multi-omics market's growth is accelerated by the growing need for targeted medicines and personalized medicine. Together, all of the previously listed elements support the market's growth. The predicted response for genome-targeted therapy by European Society for Medical Oncology was 2.73% in 2006, rose to 5.48% by the end of 2018, and has now risen to 7.04% in 2020. The anticipated response for genome-informed therapy was 3.33% in 2006, 7.68% in 2018, and 11.10% in 2020.


Multi-omics Market
Get more information on this report: Request Free Sample PDF

Multi-omics Sector: Growth Drivers and Challenges

Growth Drivers

  • Artificial intelligence and cloud computing's emergence in multi-omics data analysis - The field of life sciences is witnessing a significant opportunity for multi-omics data analysis due to the rise of cloud computing and artificial intelligence. Large and sophisticated multi-omics datasets have been created in unprecedented quantities as a result of advances in DNA sequencing technologies and other omics methods.

    For laboratories and researchers, evaluating these enormous volumes of heterogeneous biological data with conventional on-premise computing techniques is difficult and time-consuming. Large scalable computing resources that are simple to deploy on demand are provided via cloud computing. Without needing to make significant upfront financial investments in their own IT equipment, researchers can easily analyze petabytes of multi-omics datasets by utilizing elastic cloud infrastructures.
     
  • Potential of multi-omics in the creation of biomarkers for illness diagnosis - The application of multi-omics in the creation of biomarkers for disease diagnosis offers the multi-omics market a lot of potential. Integrating multi-omics techniques such as transcriptomics, proteomics, metabolomics, genomes, and epigenomics offers a more thorough understanding of biological systems and disease pathways.

    The development of biomarkers utilizing multi-omics may make it possible to diagnose illnesses accurately and early. Since most diseases are now discovered late in life, with few alternatives for treatment, there is a significant clinical need that is currently unmet. Multi-omics research offers insights that are not achievable with individual omics techniques alone by merging several forms of omics data.

    As a result, unique biomarker signatures made up of protein, genetic, and metabolic components are found. For instance, a 2021 study that combined information from over 28,000 patient samples with 11 different cancer kinds found indicators based on molecular subtypes that might be used to tailor cancer treatment.
     
  • Accurate Farming and Safety of Food - Multi-omics technologies have a lot to offer the agricultural sector in terms of improving crop yield, sustainability, and food security. Researchers can learn more about plant genetics, metabolism, and environmental responses by combining genomics, metabolomics, and other omics techniques. This knowledge can be used to design robust crop varieties that have higher yields, better nutritional quality, and more stress tolerance.

    Targeted breeding, precision fertilization, and crop management techniques that are adapted to particular environmental conditions and agronomic requirements are examples of precision agriculture practices made possible by the identification of biomarkers for disease resistance, nutrient uptake, and crop performance made easier by multiomics analysis. About 80% of the total emissions that cause CC, 88% of the FPMF impact, 55% of the FET impact, 44% of the HTnC impact, 96% of the FE impact, 93% of ME, and 96% of the TA impact are produced during the fertilization process.

Challenges

  • Exorbitant setup and infrastructure expenses for multi-omics platforms - The multi-omics market's potential for expansion is constrained by the costly infrastructure and setup costs of these platforms, which provide a major obstacle to the systems' wider adoption. Large sums of money must be spent in order to establish a multi-omics center and buy the several pricey tools required to carry out multi-omics analyses.

    These could include mass spectrometers, flow cytometers, microarrays, next-generation sequencing systems, and other specialized tools. The entire cost to build a multi-omics lab can reach millions of dollars when factoring in other costs including laboratory space, data storage systems, qualified staff, and maintenance contracts.
     
  • Obstacles posed by regulations to multi-omics adoption - The use of multi-omics technology is hampered by regulations, which is making it difficult for the multi-omics market to expand. Integrating vast volumes of disparate "omics" data, such as proteomics, metabolomics, and genomes, is known as multi-omics. It is still early in the process of creating solid analytical frameworks and validation procedures for the meaningful interpretation of such large and complicated datasets.

Multi-omics Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

15.1%

Base Year Market Size (2023)

USD 2.5 Billion

Forecast Year Market Size (2036)

USD 15.5 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Multi-omics Segmentation

End-Use (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)

By 2036, academic & research institutes segment is estimated to capture over 60% multi-omics market share. Over the projected time, it is expected that a rise in studies and research centered on multi-omics approaches such as transcriptomics, proteomics, metabolomics, and genomics will propel the segment's expansion. Additionally, funds and investments are being provided to this segment in order to carry out research in this area.

For example, the Multi-omics for Health and Disease Consortium was founded in September 2023 by the National Institutes of Health, which also funded USD 50.3 million for multi-omics research. Professionals from a number of universities, including Washington University, Columbia University, and the University of California, are part of this consortium.

Application (Cell Biology, Oncology, Neurology, Immunology)

During 2024-2036, oncology segment in the multi-omics market is anticipated to grow at more than 18.1% CAGR. Growth in this market is expected to be driven by the increasing prevalence of cancer and the expanding application of multi-omics for cancer. Numerous initiatives are being made by businesses and researchers to use multi-omics techniques to aid cancer sufferers. For example, the biotech startup Freenome initiated the Sanderson Study in September 2022, utilizing real-world data and its multiomics platform to detect certain malignancies. Segment growth is further supported by strategic expenditures made by major players in cancer research.

Product & Service (Products {Instruments, Consumables, Software}, Services)

In multi-omics market, products segment is poised to cross USD 1.8 Billion by the end of 2036. The increasing number of product launches and the spike in developments are expected to fuel the segment's expansion. Businesses are collaborating to innovate and develop new tools and platforms for multiomic research and analysis. For example, Bio-Techne and Lunaphore announced in April 2023 that they would be working together to build a fully automated spatial multiomics solution.

Over the course of the projection period, these developments are anticipated to support the segment's growth in multi-omics market. Furthermore, the creation of more effective, user-friendly goods as a result of technical improvements has improved accessibility for researchers.

Our in-depth analysis of the multi-omics market includes the following segments:

         Product & Service

  •  Products
    • Instruments
    • Consumables
    • Software
  • Services

         Type

  • Single-Cell Multi omics
  • Bulk Multi omics

          Platform

  • Genomics
  • Transcriptomics
  • Proteomics
  • Metabolomics
  • Integrated Omics Platforms

          Application

  • Cell Biology
  • Oncology
  • Neurology
  • Immunology

          End-Use

  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Multi-Omics Industry - Regional Synopsis

North America Market Statistics

North America region in multi-omics market is anticipated to dominate revenue share of around 40% by the end of 2036. Its greatest revenue share is supported by the presence of important players in the area. Additionally, businesses are making attempts to increase their visibility, which is fostering the expansion of the regional multi-omics market.

For example, in February 2023, Actuate Therapeutics and the U.S.-based company Tempus worked together to identify and further validate biomarker profiles in cancer patients. In this initiative, Tempus is utilizing the multiomics technique to enhance research and increase new scientific understandings.

The U.S. multi-omics market is quite competitive because of the rising need for thorough biological insights driven by omics technology developments. Active R&D initiatives in academia and business, where organizations compete for funds and ground-breaking discoveries, heighten this competitiveness. For example, the University of Southern California (USC) Keck School of Medicine was awarded a major 5-year research grant from the National Institutes of Health (NIH) in 2023, totaling USD 50.3 million.

European Market Analysis

The Europe region will also encounter huge growth for the multi-omics market witduring the forecast period. The expanding use of cutting-edge technologies in proteomics, metabolomics, and genomics is fueling Europe's market's strong growth. The proteomics industry in Europe was valued at USD 5,356 million in the base year.

Through supporting programs like Genome UK and the NHS Genomic Medicine Service, the United Kingdom government has demonstrated its commitment to advancing research in genomics and multi-omics. To launch the Genome Research Experiences, the National Human Genome Research Institute (NHGRI) awarded around USD 3.35 million over a five-year period in September 2022.

Due to several government efforts that are encouraging the implementation of NGS technologies in the nation, the multi-omics market in France is anticipated to increase in the near future. Targeted NGS has been supported by the French National Cancer Institute (INCa) as a standard therapeutic practice since 2013. Furthermore, the 2025 France genetic Medicine Initiative was a national plan put into action by France to guarantee that all patients have sufficient access to genetic medicine.

Germany's multi-omics market is expanding significantly due to the active involvement of government financing for research initiatives, biotech and pharmaceutical businesses, and prestigious university institutions. In 2021, the European Molecular Biology Laboratory (EMBL) in Germany organized a number of seminars and workshops with the main objective of integrating and analyzing multi-omics data.

Research Nester
Multi-omics Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Multi-Omics Landscape

    Important companies apply for product approvals in order to expand as a means of improving production and development efforts as well as to broaden the product's appeal and availability in a variety of geographic locations. Furthermore, a number of businesses are purchasing smaller competitors in an effort to improve their market share.

    • Becton, Dickinson and Company
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Thermo Fisher Scientific, Inc.
    • Illumina, Inc.
    • Danaher Corporation
    • PerkinElmer, Inc.
    • Bruker
    • Centogene N.V.
    • Element Biosciences
    • QIAGEN
    • Agilent Technologies, Inc.

In the News

  • Element Biosciences, Inc., innovative scientific technology supplier announced a collaboration with Precision Health Data Cloud leader DNAnexus. Customers can now easily transfer data from Element's AVITITM System to their DNAnexus accounts thanks to this partnership. Customers can leverage a powerful combination of capabilities by combining the outstanding performance of AVITI sequencing with the safe and extensive multi-omic analysis platform offered by DNAnexus.
  • Centogene N.V. has announced the addition of cutting-edge transcriptome analysis to its MOx diagnostic portfolio. This single-step multi-omic system, called MOx 2.0, combines biochemical testing, DNA sequencing, and recently introduced RNA sequencing to provide healthcare practitioners with an unmatched depth of diagnostic capabilities.

Author Credits:  Radhika Pawar


  • Report ID: 6091
  • Published Date: May 30, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2023, the industry size of multi-omics was over USD 2.5 billion.

The market size for multi-omics is projected to cross USD 15.5 billion by the end of 2036 expanding at a CAGR of 15.1% during the forecast period i.e., between 2024-2036.

The major players in the market are Thermo Fisher Scientific, Inc., Illumina, Inc., Danaher Corporation, PerkinElmer, Inc., Bruker, Centogene N.V., Element Biosciences, QIAGEN, Agilent Technologies, Inc., and others.

The academic & research institutes segment is anticipated to garner a share of 60% during 2024-2036.

The North America multi-omics sector is poised to hold 40% share by the end of 2036.
Multi-omics Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample